Steven M. Keller - Concepedia

Author

Steven M. Keller

Fox Chase Cancer Center

Also Known As

Costa, Daniel B., McLeod, Howard L., S M Keller, STEVEN M. KELLER, Steven Keller, Steven M Keller, Steven M. Keller

173

Publications

6.6K

Citations

H-Index

111

Concepts

All Affiliations

Fox Chase Cancer Center Montefiore Medical Center Albert Einstein College of Medicine Dana-Farber Cancer Institute Merck & Co., Inc., Rahway, NJ, USA (United States)

About

Steven M. Keller is an author at Fox Chase Cancer Center specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	48	2.9K
2	Health Sciences	16	23	885
3	Arts	2	2	77
4	Engineering	2	2	36
5	Education	1	1	61

Steven M. Keller

Publications

Citations

H-Index

Page 1

	Year	Citations
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, New England Journal of Medicine	2023	903
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud, The Lancet Oncology Interim AnalysisSurgical OncologyOncologyPembrolizumab Versus PlaceboImmunology	2022	696
A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung Cancer Steven M. Keller, Sudeshna Adak, Henry Wagner, New England Journal of Medicine	2000	450
Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M. Keller, Sudeshna Adak, Henry Wagner, The Annals of Thoracic Surgery MedicineMultiple Pulmonary NodulePathologyBronchial NeoplasmLymphatic Disease	2000	345
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer Salma K. Jabbour, Ki Hyeong Lee, Nikolaj Frost, JAMA Oncology	2021	231
Postoperative complications after combined neoadjuvant treatment of lung cancer Wyatt C. Fowler, Corey J. Langer, Walter J. Curran, The Annals of Thoracic Surgery	1993	211
Lack of Prognostic Significance of p53 and <i>K-ras</i> Mutations in Primary Resected Non–Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy Joan H. Schiller, Sudeshna Adak, Richard H. Feins, Journal of Clinical Oncology	2001	194
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer Hossein Borghaei, Corey J. Langer, Shirish M. Gadgeel, Journal of Thoracic Oncology 24-Month Overall SurvivalFirst-line TherapyOncologyPathologyImmune Checkpoint Inhibitor	2018	194
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, The Lancet OncologyAdjuvant PembrolizumabClinical TrialsImmune Checkpoint InhibitorNeoadjuvant Pembrolizumab	2024	173
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial Heather A. Wakelee, Suzanne E. Dahlberg, Steven M. Keller, The Lancet Oncology Surgical OncologyOncologyMetronomic TherapyClinical TrialsAdjuvant Chemotherapy	2017	169

Page 1